<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161946">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990288</url>
  </required_header>
  <id_info>
    <org_study_id>26078</org_study_id>
    <nct_id>NCT00990288</nct_id>
  </id_info>
  <brief_title>The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery</brief_title>
  <official_title>The Role of a Topical Hemostatic Agent in Reducing Blood Loss in Unilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the agent, Floseal, can decrease the amount of
      blood patients lose after total knee replacement (TKR) surgery. If this product can be found
      to have an effect on bleeding, it may potentially reduce the problems associated with
      bleeding after knee replacement surgery such as pain, stiffness, and the need to have a
      blood transfusion. The subject's overall participation will be over a period of 6 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fall in post-operative hemoglobin and hematocrit. Data will be collected from laboratory tests</measure>
    <time_frame>before surgery and the first and second days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drain output in milliliters at 24 hours. This will be recorded from the time the drain was inserted.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transfusion requirements - The total number of units, along with the individual number of autologous and homologous units required for each patient will be recorded.</measure>
    <time_frame>The three days following surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>3 days after surgery, 6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>3 days after surgery, 6 weeks after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Hemostatic Matrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vials of Floseal applied once at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemostatic Matrix</intervention_name>
    <arm_group_label>Hemostatic Matrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Single Knee replacement for arthritis of the knee

        Exclusion Criteria:

          -  No inflammatory arthritis (ie. Rheumatoid arthritis)

          -  No allergies to cow meat (bovine allergies

          -  No history of bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <lastchanged_date>January 11, 2011</lastchanged_date>
  <firstreceived_date>October 5, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Mark Figgie, M.D.</name_title>
    <organization>Hospital for Special Surgery</organization>
  </responsible_party>
  <keyword>To decrease blood loss during knee surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
